Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning

May-11

AUTHORS : Gillian Hall, Epidemiology Ltd, Grimsdyke House, RavenscroftPark, London EN5 4ND, United Kingdom – Email: gillian.hall@gchall.com (email provided for this study is gillian.hall@gchall.demon.co.uk , but looks like an old one)

JOURNAL : International Journal of Clinical Practice

REFERENCE: 65(5):586-91

DOI : 10.1111/j.1742-1241.2011.02648.x

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study